More Evidence That Saxagliptin Does Not Increase Risk for AMI in Diabetes
Investigators noted a major strength of this study was the ability to analyze real-word data prospectively.
Toh S, Reichman ME, Graham DJ, et al; Mini-Sentinel Saxagliptin-AMI Surveillance Writing Group. Prospective postmarketing surveillance of acute myocardial infarction in new users of saxagliptin: a population-based study [published online November 9, 2017]. Diabetes Care. doi:10.2337/dc17-0476